Dyadic International Inc. released its earnings results on May 14, 2025. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.07.

Is Dyadic International Inc. overvalued?

According to Wall Street analysts Dyadic International Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Dyadic International Inc. pay dividends?

Dyadic International Inc. does not currently pay dividends.

What is Dyadic International Inc.’s EPS estimate?

Dyadic International Inc.’s EPS estimate is -0.06.

How many shares outstanding does Dyadic International Inc. have?

Dyadic International Inc. has 30,090,660 shares outstanding.

What happened to Dyadic International Inc.’s price movement after its last earnings report?

Dyadic International Inc. reported an EPS of -$0.07 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.846%.

Which hedge fund is a major shareholder of Dyadic International Inc.?

Currently, no hedge funds are holding shares in DYAI

Dyadic International Stock Smart Score

Underperform

Fundamentals

Return on Equity

-214.26%

Trailing 12-Months

Asset Growth

-37.74%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Dyadic International Inc.

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

DYAI Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted significant progress in Dyadic's transition towards commercializing non-pharmaceutical products and securing strategic partnerships with milestone payments. However, the call also reflected concerns over reduced collaborations and a decrease in cash reserves, alongside a consistent net loss. The focus on non-pharmaceutical commercialization and milestone achievements suggests a promising outlook despite the financial challenges.Read More>